Consolidated Statement Of Profit Or Loss

Astellas Pharma Inc. - Filing #7303078

Concept 2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
Consolidated statement of profit or loss
Statement of profit or loss
Revenue
935,621,000,000 JPY
767,138,000,000 JPY
Cost of sales
173,825,000,000 JPY
143,359,000,000 JPY
Gross profit
761,795,000,000 JPY
623,779,000,000 JPY
Selling, general and administrative expenses
406,411,000,000 JPY
347,462,000,000 JPY
Other income
4,473,000,000 JPY
7,087,000,000 JPY
Other expenses
26,945,000,000 JPY
61,748,000,000 JPY
Operating profit (loss)
93,710,000,000 JPY
55,156,000,000 JPY
Finance income
4,874,000,000 JPY
6,150,000,000 JPY
Finance costs
9,543,000,000 JPY
4,989,000,000 JPY
Share of profit (loss) of investments accounted for using equity method
1,448,000,000 JPY
-237,000,000 JPY
Profit (loss) before tax
89,042,000,000 JPY
56,318,000,000 JPY
Income tax expense
15,531,000,000 JPY
20,508,000,000 JPY
Profit (loss)
JPY
JPY
JPY
73,511,000,000 JPY
JPY
JPY
73,511,000,000 JPY
JPY
JPY
JPY
73,511,000,000 JPY
JPY
JPY
JPY
JPY
JPY
35,810,000,000 JPY
JPY
JPY
35,810,000,000 JPY
JPY
35,810,000,000 JPY
JPY
JPY
JPY
JPY
Profit (loss) attributable to
Owners of parent
73,511,000,000 JPY
35,810,000,000 JPY
Earnings (loss) per share
Basic earnings (loss) per share
41.06
19.97
Diluted earnings (loss) per share
40.91
19.90

Talk to a Data Expert

Have a question? We'll get back to you promptly.